Publications by authors named "Guiseppe Pantaleo"
Background: Broadly neutralizing antibodies (bnAbs) are a promising approach for HIV-1 prevention. In the Antibody Mediated Prevention (AMP) trials, a CD4-binding site targeting bnAb, VRC01, administered intravenously (IV), demonstrated 75% prevention efficacy against highly neutralization-sensitive viruses but was ineffective against less sensitive viruses. VRC07-523LS is a next-generation bnAb targeting the CD4-binding site and was engineered for increased neutralization breadth and half-life.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the next-generation broadly neutralizing antibody (bnAb) VRC07-523LS for HIV prevention, aiming to enhance efficacy and improve administration methods compared to previous bnAbs like VRC01, which showed limited effectiveness against certain HIV strains.* -
- A total of 124 healthy participants were randomized to receive VRC07-523LS through various administration routes (IV, SC, IM) at different doses over a period of 144 weeks, analyzing safety and pharmacokinetics.* -
- Results showed that the injections were generally well-tolerated, with some mild side effects, and highlights the need for further studies on VRC07-523LS to assess its effectiveness against a broader range of
Recent data for the global burden of disease reflect major demographic and lifestyle changes, leading to a rise in non-communicable diseases. Most countries with high levels of tuberculosis face a large comorbidity burden from both non-communicable and communicable diseases. Traditional disease-specific approaches typically fail to recognise common features and potential synergies in integration of care, management, and control of non-communicable and communicable diseases.
View Article and Find Full Text PDFAs part of a European initiative (EuroVacc), we report the design, construction, and immunogenicity of two HIV-1 vaccine candidates based on a clade C virus strain (CN54) representing the current major epidemic in Asia and parts of Africa. Open reading frames encoding an artificial 160-kDa GagPolNef (GPN) polyprotein and the external glycoprotein gp120 were fully RNA and codon optimized. A DNA vaccine (DNA-GPN and DNA-gp120, referred to as DNA-C), and a replication-deficient vaccinia virus encoding both reading frames (NYVAC-C), were assessed regarding immunogenicity in Balb/C mice.
View Article and Find Full Text PDFBackground: Highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV)-1 infection allows recovery of CD4 T lymphocytes. Few studies have explored the long-term T-lymphocyte responses to HAART.
Methods: Plasma HIV-1 RNA levels and CD4 and CD8 T-lymphocyte counts were longitudinally analyzed over 4 years in 2235 participants of the Swiss HIV Cohort, commencing HAART between 1996 and 1997.